George Golumbeski

George Golumbeski

Voorzitter bij SHATTUCK LABS, INC.

Vermogen: 642 755 $ op 30-04-2024

67 jaar
Health Technology
Commercial Services
Consumer Services

Profiel

George S.
Golumbeski
is currently the Chairman at Carrick Therapeutics UK Ltd., Verseau Therapeutics, Inc., Actio Biosciences, Inc., Ananke Therapeutics, Inc., Shattuck Labs, Inc., Carrick Therapeutics Ltd., SAGE Therapeutics, Inc., Chroma Medicine, Inc., and Vertex Ventures HC.
He is also the Deputy Chairman-Supervisory Board at MorphoSys AG and the Vice Chairman at National Audubon Society, Inc. Additionally, he serves as a Director at Corbus Pharmaceuticals, Inc., BlackThorn Therapeutics, Inc., Tusk Therapeutics Ltd., and Droia Ventures.
In his former roles, Dr. Golumbeski served as the Chief Executive Officer at Nabriva Therapeutics GmbH from 2008 to 2009.
He was also the President & Director at GRAIL LLC from 2018 to 2019.
Furthermore, he held positions such as Chairman at Aura Biosciences, Inc. and BioSight Ltd., Director at Tizona Therapeutics, Inc., Pierce Biotechnology, Inc., Schwarz Pharma, Inc., EMD Pharmaceuticals, Inc., Acceleron Pharma, Inc., KSQ Therapeutics, Inc., and Enanta Pharmaceuticals, Inc., and Vice President & Director-Corporate Development at Schwarz Pharma, Inc. He was also the Senior Director-Licensing at EMD Pharmaceuticals, Inc. and the VP-Business Development, Licensing & Strategy at Novartis Oncology, Inc. Dr. Golumbeski's education includes a doctorate degree from the University of Wisconsin in 1985 and an undergraduate degree from the University of Virginia in 1979.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
01-04-2024 54 613 ( 0.11% ) 534 115 $ 30-04-2024
31-03-2024 8 000 ( 0.01% ) 108 640 $ 30-04-2024

Actieve functies van George Golumbeski

BedrijvenFunctieBegin
MORPHOSYS AG Directeur/Bestuurslid 17-05-2018
SAGE THERAPEUTICS, INC. Directeur/Bestuurslid 23-01-2019
SHATTUCK LABS, INC. Voorzitter 22-10-2021
Directeur/Bestuurslid -
Directeur/Bestuurslid -
Voorzitter -
Droia Ventures Corporate Officer/Principal 01-10-2020
Directeur/Bestuurslid 24-05-2022
Consultant / Adviseur -
░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ -
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
Alle actieve functies van George Golumbeski

Eerdere bekende functies van George Golumbeski

BedrijvenFunctieEinde
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Ervaring van George Golumbeski in detail bekijken

Opleiding van George Golumbeski

University of Wisconsin Doctorate Degree
University of Virginia Undergraduate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van George Golumbeski in detail bekijken

Connecties

100 +

Eerstegraads connecties

36

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Beursgenoteerde bedrijven6
ENANTA PHARMACEUTICALS, INC.

Health Technology

MORPHOSYS AG

Health Technology

CORBUS PHARMACEUTICALS HOLDINGS, INC.

Health Technology

SHATTUCK LABS, INC.

Health Technology

AURA BIOSCIENCES, INC.

Health Technology

SAGE THERAPEUTICS, INC.

Health Technology

Bedrijven in privébezit27

Health Technology

Electronic Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Commercial Services

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Commercial Services

Droia Ventures

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. George Golumbeski
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU